tradingkey.logo

Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder Cancer

ReutersFeb 27, 2026 3:32 PM

- Astellas Pharma Inc 4503.T:

  • PADCEV™ + KEYTRUDA® CUTS RISK OF RECURRENCE OR DEATH BY NEARLY 50% IN CISPLATIN-ELIGIBLE MUSCLE-INVASIVE BLADDER CANCER

  • ASTELLAS- SAFETY PROFILE FOR PERIOPERATIVE ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB OBSERVED IN EV-304 CONSISTENT WITH PRIOR EXPERIENCE WITH COMBINATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI